Pharmacotherapies for treatment-resistant depression / Manish K. Jha en The American Journal of Psychiatry, Año 2023 - Vol. 180 - No. 3 (Marzo)

Público ISBD [artículo]  inThe American Journal of Psychiatry > Año 2023 - Vol. 180 - No. 3 (Marzo) . - pp. 190-199 Título : Pharmacotherapies for treatment-resistant depression : how antipsychotics fit in the rapidly evolving therapeutic landscape Tipo de documento: texto impreso Autores: Manish K. Jha, Autor ; Sanjay J. Mathew, Autor Fecha de publicación: 2023 Artículo en la página: pp. 190-199 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Depresión resistente al tratamiento (TRD), Antipsicóticos atípicos, Ketamina, Esketamina, Psicodélicos, Antidepresivos, Trastornos depresivos Resumen: One in three adults with major depressive disorder (MDD) do not experience clinically significant improvement after multiple sequential courses of antidepressants and have treatment-resistant depression (TRD). The presence of TRD contributes to the morbidity and excess mortality associated with MDD and has been linked to significantly increased health care expenses. In the absence of a consensus definition of TRD, this report takes a broad approach by considering inadequate response to one or more courses of antidepressants and focuses on atypical antipsychotics that are approved by the U.S. Link: ./index.php?lvl=notice_display&id=29971 [artículo] Pharmacotherapies for treatment-resistant depression : how antipsychotics fit in the rapidly evolving therapeutic landscape [texto impreso] / Manish K. Jha, Autor ; Sanjay J. Mathew, Autor . - 2023 . - pp. 190-199. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The American Journal of Psychiatry > Año 2023 - Vol. 180 - No. 3 (Marzo) . - pp. 190-199 Palabras clave: Depresión resistente al tratamiento (TRD), Antipsicóticos atípicos, Ketamina, Esketamina, Psicodélicos, Antidepresivos, Trastornos depresivos Resumen: One in three adults with major depressive disorder (MDD) do not experience clinically significant improvement after multiple sequential courses of antidepressants and have treatment-resistant depression (TRD). The presence of TRD contributes to the morbidity and excess mortality associated with MDD and has been linked to significantly increased health care expenses. In the absence of a consensus definition of TRD, this report takes a broad approach by considering inadequate response to one or more courses of antidepressants and focuses on atypical antipsychotics that are approved by the U.S. Link: ./index.php?lvl=notice_display&id=29971

---

1 (1 - 1 / 1)